IP Library Granted Patent US 11,612,568
Granted Patent B2
US 11,612,568 · App. 16/852,342 · Granted Mar 28, 2023

Mini-tablets

Inventors: Korinde Van Den Heuvel (Wageningen, NL); Bas Van Laarhoven (Wageningen, NL); Eva Maria Janssen (Wageningen, NL); Mara Maria Wilhelmina Van Haandel (Wageningen, NL)
Assignee: DFE PHARMA GMBH & CO. KG
A61K9/2018A61K31/167
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,612,568
App. No.
16/852,342
Granted
Mar 28, 2023
Kind
B2
Abstract

The invention relates to a method for making a tablet having a diameter, as determined by the longest enveloping circle, in the range of 1 to 5 mm and/or a weight in the range of 1 to 100 mg—comprising an active ingredient selected from the group of pharmaceutical substances and active substances for a dietary supplement or nutraceutical, comprising (a) providing a lactose agglomerate comprising lactose, and a sugar alcohol; (b) providing the active ingredient; (c) mixing the agglomerate and the active ingredient, thereby obtaining a mixture; and (d) forming the tablet by direct compression.

Claims (24)

1. A method for making a tablet having a diameter, as determined by the longest enveloping circle, in the range of 1 to 5 mm and/or a weight in the range of 1 to 100 mg, the method comprising:

(a) agglomerating in a fluidized bed anhydrous lactose particles with an aqueous binding solution comprising (i) a sugar alcohol selected from the group consisting of lactitol, maltitol, sorbitol, mannitol and erythritol, and (ii) a water soluble carbohydrate comprising alpha-lactose monohydrate, thereby forming agglomerates of the lactose particles, wherein the binding solution is used in an amount of 0.05-0.25 kg dry solids in the binding solution per kg lactose agglomerate, and wherein the agglomerates comprise 80-99 wt. % anhydrous lactose and have a size, as determinable by sieving, of 600 μm or less;

(b) mixing the agglomerates with an active ingredient, and optionally one or more excipients, thereby obtaining a mixture; and

(d) forming the mixture into the tablet by direct compression.

2. The method according to claim 1 , wherein the tablet comprises at least 20 wt. %, based on total weight of the tablet, the active ingredient.

3. The method according to claim 2 , wherein the tablet comprises 30-80 wt. %, based on total weight of the tablet, the active ingredient.

4. The method according to claim 1 , wherein agglomerating is spray-agglomerating.

5. The method according to claim 1 , wherein the weight to weight ratio of total lactose to sugar alcohol in the agglomerate is in the range of 80:20 to 99:1.

6. The method according to claim 5 , wherein the weight to weight ratio of total lactose to sugar alcohol in the agglomerate is in the range of 90:10 to 97:3.

7. The method according to claim 1 , wherein the agglomerate comprises 90-99 wt. % anhydrous lactose.

8. The method according to claim 7 , wherein the agglomerate comprises 90-95 wt. % anhydrous lactose.

9. The method according to claim 1 , wherein the compression is carried out at a dwell time of 60 ms or less.

10. A method for preparing a lactose agglomerate filler in the manufacture of tablets, comprising:

agglomerating in a fluidized bed anhydrous lactose particles with an aqueous binding solution comprising (i) a sugar alcohol selected from the group consisting of lactitol, maltitol, sorbitol, mannitol and erythritol, and (ii) a water soluble carbohydrate comprising alpha-lactose monohydrate, thereby forming agglomerates of the lactose particles, wherein the binding solution is used in an amount of 0.05-0.25 kg dry solids in the binding solution per kg lactose agglomerate,

wherein the agglomerates comprise 80-99 wt. % anhydrous lactose and have a size, as determinable by sieving, of 600 μm or less.

11. The method according to claim 10 , wherein the anhydrous lactose is anhydrous beta-lactose.

12. The method according to claim 10 , wherein the binding solution is used in an amount of 0.15-0.20 kg dry solids per kg lactose agglomerate.

13. The method according to claim 10 , wherein the agglomerating is spray-agglomerating.

14. The method according to claim 10 , wherein the weight to weight ratio of total lactose to sugar alcohol in the agglomerate is in the range of 80:20 to 99:1.

15. The method according to claim 14 , wherein the weight to weight ratio of total lactose to sugar alcohol in the agglomerate is in the range of 90:10 to 97:3.

16. The method according to claim 10 , wherein the agglomerate comprises 90-99 wt. % anhydrous lactose.

17. The method according to claim 10 , further comprising mixing the agglomerates with an active ingredient, excipient, or both.

18. The method according to claim 10 , wherein the agglomerates do not comprise cellulose.

19. The method according to claim 10 , wherein the agglomerates do not comprise polymers.

Assignments (2)
CHANGE OF NAME Recorded May 29, 2020
From: DMV-FONTERRA EXCIPIENTS GMBH & CO. KG
To: DFE PHARMA GMBH & CO. KG
Reel/Frame 052792/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2020
From: VAN DEN HEUVEL, KORINDE; VAN LAARHOVEN, BAS; JANSSEN, EVA MARIA; VAN HAANDEL, MARA MARIA WILHELMINA
To: DMV-FONTERRA EXCIPIENTS GMBH & CO. KG
Reel/Frame 052779/0025 →
Priority Claims (1)
EP 17197153 · Oct 18, 2017 · regional
Continuity (2)
Continuation PCTEP2018078315 · Oct 17, 2018
Related Publication 20200237672A1 · Jul 30, 2020